Loading…
Amarin Corp Plc\uk
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AMRN.
▼ -86.2% over 5Y.
today you would have $129.41▼ -87.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $13.96 | $9.80 | $17.40 | $24.20 | |
| P/S | 24.8x | 27.2x | 17.6x | 23.2x | 26.5x |
| P/B | 12.8x | 12.7x | 8.3x | 12.9x | 16.4x |
| EPS | -$1.80 | -$4.00 | -$3.00 | -$5.20 | |
| Profit margin | -23.96% | -18.16% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CVCapsoVision, Inc | $5.93 | — | 22.5x | — | -335.06% | $296.78M |
| TLSITriSalus Life Sciences, Inc. | $4.83 | — | 45.1x | — | — | $297.41M |
| IMRXImmuneering Corp | $4.61 | — | 1.6x | — | -52.15% | $298.26M |
| TTRXTurn Therapeutics Inc. | $9.84 |
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Company description provided by Yahoo Finance.
| -35.95% |
| -19.26% |
| -28.66% |
| ROE | -13.81% | -8.45% | -16.90% | -10.71% | -17.77% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 427.8x |
| — |
| -686.28% |
| $298.82M |
| LABStandard Biotools Inc | $0.74 | — | 0.5x | — | -11.18% | $291.29M |
| FATEFATE Therapeutics Inc | $2.43 | — | 1.8x | — | -60.75% | $291.16M |